The project aims to develop Vector BioPharma’s gene delivery platform using iBET’s bioprocess and analytical methods.   The partnership between the two parties is in support of Vector Bio’s CMC (chemistry, manufacturing, and controls) development and the announcement follows the Swiss firm’s $30 million Series A fundraising in August 2022. To begin with, the multiphase partnership aims to advance an analytical method suitable for full-to-empty capsid ratio quantification from in-process as well as final purified samples. “Vector’s proprietary technology uses a…